Black Hairy Tongue Associated with Erlotinib Treatment in a Patient with Advanced Lung Cancer.

Author: Jin Seob JEONG ¹ ; Ji Yeoun LEE ; Mi Kyeong KIM ; Tae Young YOON
Author Information

1. Department of Dermatology, School of Medicine and Medical Research Institute, Chungbuk National University, Cheongju, Korea. tyyoon@chungbuk.ac.kr
Publication Type:Case Report
Keywords: Black hairy tongue; Epidermal growth factor receptor inhibitor; Erlotinib
MeSH: Butylated Hydroxytoluene; Humans; Lung; Lung Neoplasms; Middle Aged; Protein-Tyrosine Kinases; Quinazolines; Receptor, Epidermal Growth Factor; Tongue, Hairy; Erlotinib Hydrochloride
From:Annals of Dermatology 2011;23(4):526-528
CountryRepublic of Korea
Language:English
Abstract: Erlotinib is a tyrosine kinase inhibitor that acts on the epidermal growth factor receptor (EGFR). There have been many reports of the mucocutaneous side effects related to several EGFR inhibitors (EGFRIs). However, no case of black hairy tongue (BHT) associated with EGFRI has been reported. Herein, we report the first case of erlotinib-induced BHT in a 61-year-old man with advanced lung cancer. Considering recent use of EGFRIs worldwide, dermatologists should recognize the possible occurrence of BHT associated with EGFRIs such as erlotinib.